Renal impairment and use of nephrotoxic agents in patients with multiple myeloma in the clinical practice setting in the United States
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Medicine"
DOI: 10.1002/cam4.1075
Abstract: Renal impairment is a common complication of multiple myeloma and deterioration in renal function or renal failure may complicate clinical management. This retrospective study in patients with multiple myeloma using an electronic medical records database… read more here.
Keywords: myeloma; diagnosis; multiple myeloma; nephrotoxic agents ... See more keywords
Physiologically‐Based Pharmacokinetic Modelling to Investigate Baricitinib and Tofacitinib Dosing Recommendations for COVID‐19 in Geriatrics
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology and Therapeutics"
DOI: 10.1002/cpt.2600
Abstract: Janus kinase (JAK) inhibitors baricitinib and tofacitinib are recommended by the US National Institutes of Health as immunomodulatory drugs for coronavirus disease 2019 (COVID‐19) treatment. In addition, baricitinib has recently received Emergency Use Authorization from… read more here.
Keywords: baricitinib; based pharmacokinetic; renal impairment; baricitinib tofacitinib ... See more keywords
Pharmacokinetics of Oral Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of COVID‐19, in Subjects With Renal Impairment
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology and Therapeutics"
DOI: 10.1002/cpt.2688
Abstract: Nirmatrelvir coadministered with ritonavir is highly efficacious in reducing the risk of coronavirus disease 2019 (COVID‐19) adverse outcomes among patients at increased risk of progression to severe disease, including patients with chronic kidney disease. Because… read more here.
Keywords: impairment pharmacokinetics; nirmatrelvir ritonavir; impairment; renal impairment ... See more keywords
Renal impairment and analgesia: From effectiveness to adverse effects
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Cellular Physiology"
DOI: 10.1002/jcp.28506
Abstract: Kidney pain is one of the clinically significant features of renal dysfunction. Mild to severe pain is seen in the lower back area. Painkillers are mostly recommended in these cases to relieve the symptom. Yet,… read more here.
Keywords: analgesia effectiveness; renal impairment; impairment analgesia; adverse effects ... See more keywords
Moderate Renal Impairment Does Not Impact the Ability of CSL112 (Apolipoprotein A‐I [Human]) to Enhance Cholesterol Efflux Capacity
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Pharmacology"
DOI: 10.1002/jcph.1337
Abstract: CSL112 (apolipoprotein A‐I [human]) is a novel intravenous formulation of plasma‐derived apolipoprotein A‐I (apoA‐I) that enhances cholesterol efflux capacity. Renal impairment is a common comorbidity in acute myocardial infarction patients and is associated with impaired… read more here.
Keywords: moderate renal; csl112; renal impairment; efflux capacity ... See more keywords
Drug–Drug Interactions in People Living With HIV at Risk of Hepatic and Renal Impairment: Current Status and Future Perspectives
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Pharmacology"
DOI: 10.1002/jcph.2025
Abstract: Despite the advancement of antiretroviral therapy (ART) for the treatment of human immunodeficiency virus (HIV), drug–drug interactions (DDIs) remain a relevant clinical issue for people living with HIV receiving ART. Antiretroviral (ARV) drugs can be… read more here.
Keywords: living hiv; people living; renal impairment; drug ... See more keywords
Pharmacokinetics and Safety of Imeglimin in Japanese Patients with Impaired Renal Function.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of clinical pharmacology"
DOI: 10.1002/jcph.2218
Abstract: Imeglimin is a diabetic drug excreted mainly in the urine; therefore, the impact of renal impairment on its pharmacokinetics (PK) is of interest. We assessed the PK and safety of imeglimin in Japanese patients with… read more here.
Keywords: function; safety imeglimin; renal impairment; renal function ... See more keywords
Physiologically based pharmacokinetic modeling characterizes the drug-drug interaction between saxagliptin and rifampicin in patients with renal impairment.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of clinical pharmacology"
DOI: 10.1002/jcph.2223
Abstract: The aim of the present study is to develop physiologically based pharmacokinetic (PBPK) models for saxagliptin and its active metabolite, 5-hydroxy saxagliptin, and to predict the effect of co-administration of rifampicin, a strong inducer of… read more here.
Keywords: hydroxy saxagliptin; renal impairment; rifampicin; drug ... See more keywords
The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Pharmacology"
DOI: 10.1002/jcph.955
Abstract: Ertugliflozin is a highly selective and potent inhibitor of the sodium‐glucose cotransporter 2 in development for the treatment of type 2 diabetes mellitus. The glycemic efficacy of sodium‐glucose cotransporter 2 inhibitors such as ertugliflozin depends… read more here.
Keywords: effect renal; type diabetes; diabetes mellitus; impairment pharmacokinetics ... See more keywords
The renal elimination of apixaban: the totality of data relating to the renal clearance of apixaban in patients with impaired renal function: response to Hellfritzsch et al.
Sign Up to like & getrecommendations! Published in 2017 at "Pharmacoepidemiology and Drug Safety"
DOI: 10.1002/pds.4163
Abstract: Hellfritzsch et al. discuss an apparent lack of consistency in reporting of renal elimination data among novel oral anticoagulant drugs: with a focus on apixaban.1 We would like to provide the totality of data that… read more here.
Keywords: apixaban; renal clearance; clearance; renal impairment ... See more keywords
Risk of nephrogenic systemic fibrosis (NSF) in oncology patients receiving gadoxetic acid and updated risk of estimate of NSF in patients receiving gadoxetic acid with moderate and severe renal impairment
Sign Up to like & getrecommendations! Published in 2022 at "Abdominal Radiology"
DOI: 10.1007/s00261-021-03367-3
Abstract: Objectives Gadoxetic acid (GA) is a half-biliary excreted gadolinium-based contrast agent (GBCA) administered at lower dose than gadobenic acid with similar ionic structure. Gadobenic acid is considered low-risk for nephrogenic systemic fibrosis (NSF) in patients… read more here.
Keywords: risk; renal impairment; acid; oncology ... See more keywords